GBA's "2021 Stock Phantasma"
- Thread starter stonedinvestor
- Start date
GOOGLE SHOPPIFY HOOK UP!!! SHOP SPIKING.
An Etherium Market....
Now we sit back an laugh. I'm so glad Crypto is crashing. That dumb bastard Cramer he jumped right in at the top and led his lemmings in...
Now we sit back an laugh. I'm so glad Crypto is crashing. That dumb bastard Cramer he jumped right in at the top and led his lemmings in...
link?
You make it sound like he was the only person to ever pump crypto's.
Our commercial is gone Stoney, its safe to turn the volume back up on CNBC.
A Lesson In Perficiant Thinking--
I've known about this stock for ages. Perficiant. I don't pretend to understand the story.
Client Relationships are very important: Perficient has built long-term relationships with many of its clients, which continue to engage it for additional projects. Recurrent business is a fundamental part of Perficient's growth plan. And in that sense they have really executed.
In the past 5 years all these cloud based whatever stocks have come and go and Perficiant is still there ticking away. Whatever they do-- It's sticky.- cloud-based managed services
While the historical EPS growth rate for Perficient is 23.4%, investors should actually focus on the projected growth. The company's EPS is expected to grow 24.7% this year, crushing the industry average, which calls for EPS growth of 16.4%.
There have been upward revisions in current-year earnings estimates for Perficient. The Zacks Consensus Estimate for the current year has surged 6.6% over the past month.
WHAT'S UP!!!!!!
Agrify Corporation (AGFY)-- WHERE IS THE LOVE!!!!
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
$9.18+1.56 (+20.47%)<-------------------
At close: May 18 4:00PM EDT
I've known about this stock for ages. Perficiant. I don't pretend to understand the story.
Client Relationships are very important: Perficient has built long-term relationships with many of its clients, which continue to engage it for additional projects. Recurrent business is a fundamental part of Perficient's growth plan. And in that sense they have really executed.
In the past 5 years all these cloud based whatever stocks have come and go and Perficiant is still there ticking away. Whatever they do-- It's sticky.- cloud-based managed services
While the historical EPS growth rate for Perficient is 23.4%, investors should actually focus on the projected growth. The company's EPS is expected to grow 24.7% this year, crushing the industry average, which calls for EPS growth of 16.4%.
There have been upward revisions in current-year earnings estimates for Perficient. The Zacks Consensus Estimate for the current year has surged 6.6% over the past month.
WHAT'S UP!!!!!!
Agrify Corporation (AGFY)-- WHERE IS THE LOVE!!!!
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
$9.18+1.56 (+20.47%)<-------------------
At close: May 18 4:00PM EDT
LINK! I WATCHED THE DAMN SHOW WHEN HE HAD THE STEAK JUICE RUNNING OUT OF HIS MOUTH AND HE WAS TALKING ABOUT BUYING A HOUSE WITH ETHERIUM.... This after years of mocking it... just goes to show... Anyone can be a dupe.
They say once you touch that Knightscope robot you instantly get a urinary infection.
Then it provides a Rx and a single cup of very tart cranberry juice.
Then it provides a Rx and a single cup of very tart cranberry juice.
This is going to be difficult-- One of the harder to read press releases...
Histogen, Amerimmune report publication on emricasan in COVID-19 08:13 HSTO Histogen and its partner, Amerimmune reported the publication of the potential utility of emricasan in COVID-19 in Allergy, the official Journal of the European Academy of Allergy and Clinical Immunology.
Ok 1-- published in an allergy journal is weird.
Amerimmune, in collaboration with Dr. Raavi Gupta from SUNY Downstate Medical Center and Dr. Lishomva Ndhlovu from Weill Cornell Medicine, demonstrated the impact of caspases in multiple blood cells beyond the acute stage of the disease.
Ok 2-- Raavi Gupta... is he related to the Dr Gupta who has been on CNN so much? I would bet. Maybe the same guy?
Their research concluded that caspases are elevated in patients with co-morbidities and persisted into much later stages of the disease, also referred to as long COVID. Moreover, the results were not just limited to the elevation of caspase-1 in white blood cells. There was also an elevation of caspase-3 in red blood cells. These findings have potential implications to understand the pathogenesis of complications of SARS-CoV2 infection such as extensive blood clot formation, resulting in significant morbidity and mortality.
The collaborative work of SUNY Downstate and Weill Cornell Medical Center with Amerimmune demonstrated how in certain individuals regarded as "high risk", such as asthma, immune deficiencies and chronic sinopulmonary disease, there is already increased baseline caspase-1 expression, potentially setting the stage for complications if they were to be infected with SARS CoV2. All the assays used in this study were developed and validated by Amerimmune. This study now leads to more research opportunities to explore why some individuals develop worse outcomes, whereas some others remain asymptomatic.
Most importantly, the team showed that Emricasan, a pan-caspase inhibitor, can effectively reduce the caspase expression in in vitro, paving the way to the use of pan-caspase inhibition as a treatment modality in COVID-19. "Emricasan is a small molecule pan-caspase inhibitor that is administered orally, which has been shown to reduce caspase related inflammation in tissues. This therapeutic modality could address the events at the onset of the COVID-19 process and may have the potential to prevent the down-stream COVID-19 related complications," said Oral Alpan, MD, CEO of Amerimmune.
"The findings from this important research support the potential of emricasan as a treatment option for COVID-19 in the acute and long-haul phases of the disease," said Richard Pascoe, President and CEO of Histogen. "We look forward to the anticipated completion of our ongoing Phase 1 Study in mild- symptomatic COVID-19 patients at SUNY Downstate Medical Center, in the second quarter of 2021."
Ok HSTO is a failed IPO for NASH liver symptoms who has purchased a company Conatus a ways back who had this drug Emricasan...
HSTO also has:
HST 001 – Hair Stimulating Complex (HSC)
Histogen’s lead product application is a Hair Stimulating Complex (HSC), intended to be a physician-administered therapeutic for alopecia (hair loss). HSC is anticipated to be a safe, minimally-invasive treatment that promotes new hair growth where existing treatments only reduce hair loss.
HSC is manufactured to enrich for growth factors including KGF, VEGF, and follistatin, which are involved in signaling stem cells in the body, and have been shown to be important in hair formation and the stimulation of resting hair follicles. Follistatin in particular has been linked to hair follicle stem cell proliferation.
Clinical Development
Histogen is advancing its HSC program into a Phase 1b/2a Clinical Trial (US IND 108935) to evaluate the safety and efficacy of HSC in male pattern hair loss. Three previous Company-sponsored proof-of-concept clinical trials have been completed in male pattern and female diffuse hair loss. In one trial, 84.6% of men treated showed new terminal hair growth and treatment was well tolerated.
In the second clinical trial, statistically significant and cosmetically relevant improvements were observed in total hair count, terminal hairs and hair thickness at 12 weeks, with hair growth parameters remaining substantially above baseline one year post-treatment.
So HSTO is way cheap at $1.00 / Lets watch this CAREFULLY!
Histogen, Amerimmune report publication on emricasan in COVID-19 08:13 HSTO Histogen and its partner, Amerimmune reported the publication of the potential utility of emricasan in COVID-19 in Allergy, the official Journal of the European Academy of Allergy and Clinical Immunology.
Ok 1-- published in an allergy journal is weird.
Amerimmune, in collaboration with Dr. Raavi Gupta from SUNY Downstate Medical Center and Dr. Lishomva Ndhlovu from Weill Cornell Medicine, demonstrated the impact of caspases in multiple blood cells beyond the acute stage of the disease.
Ok 2-- Raavi Gupta... is he related to the Dr Gupta who has been on CNN so much? I would bet. Maybe the same guy?
Their research concluded that caspases are elevated in patients with co-morbidities and persisted into much later stages of the disease, also referred to as long COVID. Moreover, the results were not just limited to the elevation of caspase-1 in white blood cells. There was also an elevation of caspase-3 in red blood cells. These findings have potential implications to understand the pathogenesis of complications of SARS-CoV2 infection such as extensive blood clot formation, resulting in significant morbidity and mortality.
The collaborative work of SUNY Downstate and Weill Cornell Medical Center with Amerimmune demonstrated how in certain individuals regarded as "high risk", such as asthma, immune deficiencies and chronic sinopulmonary disease, there is already increased baseline caspase-1 expression, potentially setting the stage for complications if they were to be infected with SARS CoV2. All the assays used in this study were developed and validated by Amerimmune. This study now leads to more research opportunities to explore why some individuals develop worse outcomes, whereas some others remain asymptomatic.
Most importantly, the team showed that Emricasan, a pan-caspase inhibitor, can effectively reduce the caspase expression in in vitro, paving the way to the use of pan-caspase inhibition as a treatment modality in COVID-19. "Emricasan is a small molecule pan-caspase inhibitor that is administered orally, which has been shown to reduce caspase related inflammation in tissues. This therapeutic modality could address the events at the onset of the COVID-19 process and may have the potential to prevent the down-stream COVID-19 related complications," said Oral Alpan, MD, CEO of Amerimmune.
"The findings from this important research support the potential of emricasan as a treatment option for COVID-19 in the acute and long-haul phases of the disease," said Richard Pascoe, President and CEO of Histogen. "We look forward to the anticipated completion of our ongoing Phase 1 Study in mild- symptomatic COVID-19 patients at SUNY Downstate Medical Center, in the second quarter of 2021."
Ok HSTO is a failed IPO for NASH liver symptoms who has purchased a company Conatus a ways back who had this drug Emricasan...
HSTO also has:
HST 001 – Hair Stimulating Complex (HSC)
Histogen’s lead product application is a Hair Stimulating Complex (HSC), intended to be a physician-administered therapeutic for alopecia (hair loss). HSC is anticipated to be a safe, minimally-invasive treatment that promotes new hair growth where existing treatments only reduce hair loss.
HSC is manufactured to enrich for growth factors including KGF, VEGF, and follistatin, which are involved in signaling stem cells in the body, and have been shown to be important in hair formation and the stimulation of resting hair follicles. Follistatin in particular has been linked to hair follicle stem cell proliferation.
Clinical Development
Histogen is advancing its HSC program into a Phase 1b/2a Clinical Trial (US IND 108935) to evaluate the safety and efficacy of HSC in male pattern hair loss. Three previous Company-sponsored proof-of-concept clinical trials have been completed in male pattern and female diffuse hair loss. In one trial, 84.6% of men treated showed new terminal hair growth and treatment was well tolerated.
In the second clinical trial, statistically significant and cosmetically relevant improvements were observed in total hair count, terminal hairs and hair thickness at 12 weeks, with hair growth parameters remaining substantially above baseline one year post-treatment.
So HSTO is way cheap at $1.00 / Lets watch this CAREFULLY!
On the Gupta front: Raavi appears o be a women and a fine Dr in Brooklyn. Maybe related to CNBC guy? Or Gupta is just a popular name in India. Unfortunately for Dr Raavi there is a Bollywood actress named Ravee Gupta and she absolutely devours the internet... page after page...